相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C19and Proton Pump Inhibitor Dosing
John J. Lima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Impact of theCYP2C19*17Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Craig R. Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2021)
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
Joshua P. Lewis et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2020)
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial
Amy Damask et al.
CIRCULATION (2020)
Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis
Matthew W. Segar et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis
Maxime Meloche et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis
Innocent G. Asiimwe et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites
Richard M. Turner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study
Anne Kristine Anstensrud et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI Results of the GIANT Study
Jean-Sebastien Hulot et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel The ABCD-GENE Score
Dominick J. Angiolillo et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Trends in anticoagulant prescribing: a review of local policies in English primary care
Katherine H. Ho et al.
BMC HEALTH SERVICES RESEARCH (2020)
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial
Richard J. Marrero et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Network Medicine: A Clinical Approach for Precision Medicine and Personalized Therapy in Coronary Heart Disease
Teresa Infante et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Recommendations for Clinical Warfarin Genotyping Allele Selection A Report of the Association for Molecular Pathology and the College of American Pathologists
Victoria M. Pratt et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Association ofSLCO1B1c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms
Derek W. Linskey et al.
PHARMACOGENETICS AND GENOMICS (2020)
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
Jemma C. Hopewell et al.
EUROPEAN HEART JOURNAL (2020)
Pharmacogenetic factors affecting β-blocker metabolism and response
Cameron D. Thomas et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
Heart Failure With Reduced Ejection Fraction A Review
Sean P. Murphy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
Naveen L. Pereira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature
Daniel M. F. Claassens et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Genotype-Guided Hydralazine Therapy
Kimberly S. Collins et al.
AMERICAN JOURNAL OF NEPHROLOGY (2020)
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing
Yee Ming Lee et al.
PHARMACOGENETICS AND GENOMICS (2019)
Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
Andrea L. Jorgensen et al.
BMC MEDICINE (2019)
Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication
Arjun P. Athreya et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
A longitudinal big data approach for precision health
Sophia Miryam Schussler-Fiorenza Rose et al.
NATURE MEDICINE (2019)
Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink
Daniel F. Carr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy
Lyrialle W. Han et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals
Elisa Danese et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center
Emili Leary et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2019)
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
Marco Proietti et al.
STROKE (2018)
Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease
Florian Schlotter et al.
CIRCULATION (2018)
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy
Philip E. Empey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects
Simona Volpi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome
Dan M. Roden et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Larisa H. Cavallari et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2018)
Ticagrelor-related late-onset dyspnea as cause of emergency department visit: a 3-year outpatient study
Niccolo Lombardi et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2018)
Recommendations for Clinical CYP2C19 Genotyping Allele Selection A Report of the Association for Molecular Pathology
Victoria M. Pratt et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes The PHARMCLO Trial
Francesca Maria Notarangelo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/N MA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Paul K. Whelton et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017
Junya Zhu et al.
PHARMACOTHERAPY (2018)
Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the rubber effect
Panayiotis D. Ziakas et al.
PLOS ONE (2018)
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
Elias J. Dayoub et al.
JAMA INTERNAL MEDICINE (2018)
Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy
Lisa Gross et al.
THROMBOSIS AND HAEMOSTASIS (2018)
ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to beta-blockers in patients with heart failure
Jin Huang et al.
CELL DISCOVERY (2018)
The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care
Jason L. Vassy et al.
CONTEMPORARY CLINICAL TRIALS (2018)
Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent
Tanima De et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings
Bruce Peyser et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2018)
The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database
Andrea Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack A Systematic Review and Meta-Analysis
Yuesong Pan et al.
CIRCULATION (2017)
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach
M. J. Arwood et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Kelly E. Caudle et al.
GENETICS IN MEDICINE (2017)
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015
Lars J. Kjerpeseth et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease
Yajing Zhai et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty The GIFT Randomized Clinical Trial
Brian F. Gage et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
Ajay Gupta et al.
LANCET (2017)
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
William R. Hiatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
George Ntaios et al.
STROKE (2017)
Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)
Oyunbileg Magvanjav et al.
STROKE (2017)
Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites
Mohammad-Reza Rouini et al.
THERAPIE (2017)
Pharmocogentics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics(RNPGx)
Fabien Lamoureux et al.
THERAPIE (2017)
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies
Dominick J. Angiolillo et al.
CIRCULATION (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Clyde W. Yancy et al.
CIRCULATION (2017)
Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting
Pradeep Natarajan et al.
CIRCULATION (2017)
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting
L. H. Cavallari et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk A Pilot Study
David G. Strauss et al.
CIRCULATION (2017)
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes
Jessica L. Mega et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2016)
Switching P2Y(12)-receptor inhibitors in patients with coronary artery disease
Fabiana Rollini et al.
NATURE REVIEWS CARDIOLOGY (2016)
Implementation of inpatient models of pharmacogenetics programs
Larisa H. Cavallari et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
Joshua C. Denny et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 17 (2016)
Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender
Jian Shi et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Physician Response to Implementation of Genotype-Tailored Antiplatelet Therapy
J. F. Peterson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent
Jesus Sanchez-Ramos et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack
Yilong Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population
De-Liang Shen et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease
Glenn N. Levine et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2016)
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty
Xando Diaz-Villamarin et al.
PHARMACOGENOMICS (2016)
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel Insights from the ELEVATE-TIMI 56 Trial
Edward T. Carreras et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
B. A. L. M. Deiman et al.
NETHERLANDS HEART JOURNAL (2016)
Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention
Francesco Franchi et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2015)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
J. K. Hicks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
Kosuke Doki et al.
DRUG METABOLISM AND PHARMACOKINETICS (2015)
Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics
A. Stewart et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Jessica L. Mega et al.
LANCET (2015)
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Jessica L. Mega et al.
LANCET (2015)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Aleksi Tornio et al.
PHARMACOGENETICS AND GENOMICS (2015)
Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
Hee Youn Choi et al.
PHARMACOGENETICS AND GENOMICS (2015)
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans
Katarzyna Drozda et al.
PHARMACOGENETICS AND GENOMICS (2015)
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Sanjiv J. Shah et al.
CIRCULATION (2015)
In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study
Iris Postmus et al.
ATHEROSCLEROSIS (2014)
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel A Meta-Analysis
Michael J. Sorich et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2014)
An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT-HF Substudy
J. A. Batty et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update
L. B. Ramsey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease
Baolei Guo et al.
JOURNAL OF VASCULAR SURGERY (2014)
Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization
Dan E. Arking et al.
NATURE GENETICS (2014)
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study
Catherine E. de Keyser et al.
PHARMACOGENETICS AND GENOMICS (2014)
Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension
Lizania Borges Spinasse et al.
PHARMACOGENOMICS (2014)
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy
Jacqueline S. Danik et al.
AMERICAN HEART JOURNAL (2013)
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding
Guillaume Pare et al.
CIRCULATION (2013)
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink
D. F. Carr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
C. M. Blake et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation
David P. Kao et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial
Xiang Xie et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
Minoli A. Perera et al.
LANCET (2013)
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
Lara M. Mangravite et al.
NATURE (2013)
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Munir Pirmohamed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
Joshua P. Lewis et al.
PHARMACOGENETICS AND GENOMICS (2013)
Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service
Edith A. Nutescu et al.
PHARMACOTHERAPY (2013)
Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis
Catherine Buettner et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism
Y. Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel
Michel Zabalza et al.
HEART (2012)
Influence of Genetic Polymorphisms on the Effect of High-and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention The GIFT (Genotype Information and Functional Testing) Study
Matthew J. Price et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans
Adam Bress et al.
PHARMACOGENOMICS (2012)
Mechanisms of statin-induced myalgia assessed by physiogenomic associations
Gualberto Ruano et al.
ATHEROSCLEROSIS (2011)
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients
Jean-Sebastien Hulot et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2011)
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response
J. P. Lewis et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Clinical Importance of OATP1B1 and OATP1B3 in Drug-Drug Interactions
Yoshihisa Shitara
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
Richard C. Becker et al.
EUROPEAN HEART JOURNAL (2011)
Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype
A. Gonzalez-Fierro et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis
Michael V. Holmes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort
Michel R. Hoenig et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Paraoxonase-1 is a major determinant of clopidogrel efficacy
Heleen J. Bouman et al.
NATURE MEDICINE (2011)
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients
Maximilian T. Lobmeyer et al.
PHARMACOGENETICS AND GENOMICS (2011)
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics
Daniel Sehrt et al.
PHARMACOGENOMICS (2011)
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
Tim Bauer et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events
Klaus A. Tiroch et al.
AMERICAN HEART JOURNAL (2010)
Relation of ADRB1, CYP2D6, and UGT1A1 Polymorphisms With Dose of, and Response to, Carvedilol or Metoprolol Therapy in Patients With Chronic Heart Failure
Linnea M. Baudhuin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Nita A. Limdi et al.
BLOOD (2010)
Do selected drugs increase the risk of lupus? A matched case-control study
W. Marieke Schoonen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Dirk Sibbing et al.
CIRCULATION (2010)
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
L. H. Cavallari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Changes in the QTc Interval After Administration of Flecainide Acetate, With and Without Coadministered Paroxetine, in Relation to Cytochrome P450 2D6 Genotype: Data From an Open-Label, Two-Period, Single-Sequence Crossover Study in Healthy Korean Male Subjects
Kyoung Soo Lim et al.
CLINICAL THERAPEUTICS (2010)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese
Pei-Chieng Cha et al.
HUMAN MOLECULAR GENETICS (2010)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis
Jean-Sebastien Hulot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA Boxed Warning A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
David R. Holmes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis
C. Combescure et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
Jessica L. Mega et al.
LANCET (2010)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin et al.
LANCET (2010)
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism
Mary V. Relling et al.
LANCET ONCOLOGY (2010)
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy
Matthijs L. Becker et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Clopidogrel pathway
Katrin Sangkuhl et al.
PHARMACOGENETICS AND GENOMICS (2010)
The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology
Colin J. D. Ross et al.
THYROID (2010)
Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis
Betti Giusti et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
The largest prospective warfarin-treated cohort supports genetic forecasting
Mia Wadelius et al.
BLOOD (2009)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Jessica L. Mega et al.
CIRCULATION (2009)
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Christoph Varenhorst et al.
EUROPEAN HEART JOURNAL (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial
Dennis M. Mcnamara et al.
JOURNAL OF CARDIAC FAILURE (2009)
Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure
Sharon Cresci et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects
Deepak Voora et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet et al.
LANCET (2009)
CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
Matthew G. McDonald et al.
MOLECULAR PHARMACOLOGY (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Danxin Wang et al.
BLOOD (2008)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
B. F. Gage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
β-Adrenergic Receptor Gene Polymorphisms and β-Blocker Treatment Outcomes in Hypertension
M. A. Pacanowski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Elliott M. Antman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
K. Umemura et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure
Stephen B. Liggett et al.
NATURE MEDICINE (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin
Na Limdi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension
Jean Lefebvre et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus
Lynda Mazari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
Kosuke Doki et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure
Stephen B. Liggett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
β1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension
Jie Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment
M Fiegenbaum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele
SC Sim et al.
PHARMACOGENETICS AND GENOMICS (2005)
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage
RA Wilke et al.
PHARMACOGENETICS AND GENOMICS (2005)
β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure
SG Terra et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
S Rost et al.
NATURE (2004)
Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
AC Allabi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension
I Zineh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
DM McNamara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study
HL White et al.
EUROPEAN JOURNAL OF HEART FAILURE (2003)
β1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol
JA Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
MG Scordo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
MK Higashi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Polymorphisms in OATP-C -: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
RG Tirona et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
LJ Dickmann et al.
MOLECULAR PHARMACOLOGY (2001)
分享论文
